Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1984 Nov;59(11):1052–1060. doi: 10.1136/adc.59.11.1052

Maternal drug histories and central nervous system anomalies.

K A Winship, D A Cahal, J C Weber, J P Griffin
PMCID: PMC1628833  PMID: 6150687

Abstract

Prescription data for the three months before the last menstrual period and for the first trimester of pregnancy were obtained for 764 mothers whose children had a defect of the central nervous system and for an equal number of mothers of control babies born from the same doctors' practices. There was a statistically significant difference overall between the numbers of mothers who were prescribed drugs in the study and control groups during the trimester before the last menstrual period but no such difference was found for the first pregnancy trimester, nor was there a significant difference for any specific group of drugs. For a composite group of non-steroid anti-inflammatory drugs, salicylates, and sulphasalazine there was a significant difference for the trimester before the last menstrual period. There are arguments against such an artificial grouping, however, and when the individual drugs were considered the comparisons were no longer significant. The odds ratios for all medicines containing folic acid taken in the trimester before the last menstrual period were considerably less than unity, in contrast with nearly all other comparisons. This supports a suggested protective effect against neural tube defects of folic acid supplements begun before the onset of pregnancy but the odds ratios of these comparisons were not statistically significant.

Full text

PDF
1052

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Craxi A., Pagliarello F. Possible embryotoxicity of sulfasalazine. Arch Intern Med. 1980 Dec;140(12):1674–1674. doi: 10.1001/archinte.140.12.1674c. [DOI] [PubMed] [Google Scholar]
  2. Cuckle H. S., Wald N. J. Evidence against oral contraceptives as a cause of neural-tube defects. Br J Obstet Gynaecol. 1982 Jul;89(7):547–549. doi: 10.1111/j.1471-0528.1982.tb03657.x. [DOI] [PubMed] [Google Scholar]
  3. Danks D. M., Halliday J. L. Incidence of neural tube defects in Victoria, Australia. Lancet. 1983 Jan 1;1(8314-5):65–65. doi: 10.1016/s0140-6736(83)91593-3. [DOI] [PubMed] [Google Scholar]
  4. DonnaiD, Harris R. Unusual fetal malformations after antiemetics in early pregnancy. Br Med J. 1978 Mar 18;1(6114):691–692. doi: 10.1136/bmj.1.6114.691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Field B., Kerr C., Mathers C. D. Incidence of neural-tube defects. Dev Med Child Neurol. 1982 Dec;24(6):861–862. doi: 10.1111/j.1469-8749.1982.tb13712.x. [DOI] [PubMed] [Google Scholar]
  6. Golding J., Vivian S., Baldwin J. A. Maternal anti-nauseants and clefts of lip and palate. Hum Toxicol. 1983 Jan;2(1):63–73. doi: 10.1177/096032718300200105. [DOI] [PubMed] [Google Scholar]
  7. Greenberg G., Inman W. H., Weatherall J. A., Adelstein A. M., Haskey J. C. Maternal drug histories and congenital abnormalities. Br Med J. 1977 Oct 1;2(6091):853–856. doi: 10.1136/bmj.2.6091.853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Harron D. W., Griffiths K., Shanks R. G. Debendox and congenital malformations in Northern Ireland. Br Med J. 1980 Nov 22;281(6252):1379–1381. doi: 10.1136/bmj.281.6252.1379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Khan A. K., Truelove S. C. Placental and mammary transfer of sulphasalazine. Br Med J. 1979 Dec 15;2(6204):1553–1553. doi: 10.1136/bmj.2.6204.1553. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Leck I. Causation of neural tube defects: clues from epidemiology. Br Med Bull. 1974 May;30(2):158–163. doi: 10.1093/oxfordjournals.bmb.a071187. [DOI] [PubMed] [Google Scholar]
  11. MANTEL N., HAENSZEL W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959 Apr;22(4):719–748. [PubMed] [Google Scholar]
  12. Milkovich L., van den Berg B. J. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstet Gynecol. 1976 May 15;125(2):244–248. doi: 10.1016/0002-9378(76)90601-3. [DOI] [PubMed] [Google Scholar]
  13. Nelson M. M., Forfar J. O. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. Br Med J. 1971 Mar 6;1(5748):523–527. doi: 10.1136/bmj.1.5748.523. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Newman N. M., Correy J. F. Possible teratogenicity of sulphasalazine. Med J Aust. 1983 May 28;1(11):528–529. doi: 10.5694/j.1326-5377.1983.tb136199.x. [DOI] [PubMed] [Google Scholar]
  15. Nora J. J., Nora A. H., Blu J., Ingram J., Fountain A., Peterson M., Lortscher R. H., Kimberling W. J. Exogenous progestogen and estrogen implicated in birth defects. JAMA. 1978 Sep 1;240(9):837–843. [PubMed] [Google Scholar]
  16. Patterson D. C. Congenital deformities associated with Benedectin. Can Med Assoc J. 1977 Jun 18;116(12):1348–1348. [PMC free article] [PubMed] [Google Scholar]
  17. Robinson S. C. Pregnancy outcome following oral contraceptives. Am J Obstet Gynecol. 1971 Feb 1;109(3):354–358. doi: 10.1016/0002-9378(71)90328-0. [DOI] [PubMed] [Google Scholar]
  18. Shapiro S., Heinonen O. P., Siskind V., Kaufman D. W., Monson R. R., Slone D. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol. 1977 Jul 1;128(5):480–485. doi: 10.1016/0002-9378(77)90028-x. [DOI] [PubMed] [Google Scholar]
  19. Slone D., Siskind V., Heinonen O. P., Monson R. R., Kaufman D. W., Shapiro S. Aspirin and congenital malformations. Lancet. 1976 Jun 26;1(7974):1373–1375. doi: 10.1016/s0140-6736(76)93025-7. [DOI] [PubMed] [Google Scholar]
  20. Smithells R. W., Nevin N. C., Seller M. J., Sheppard S., Harris R., Read A. P., Fielding D. W., Walker S., Schorah C. J., Wild J. Further experience of vitamin supplementation for prevention of neural tube defect recurrences. Lancet. 1983 May 7;1(8332):1027–1031. doi: 10.1016/s0140-6736(83)92654-5. [DOI] [PubMed] [Google Scholar]
  21. Smithells R. W., Sheppard S., Schorah C. J., Seller M. J., Nevin N. C., Harris R., Read A. P., Fielding D. W. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. Arch Dis Child. 1981 Dec;56(12):911–918. doi: 10.1136/adc.56.12.911. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Smithells R. W., Sheppard S. Teratogenicity testing in humans: a method demonstrating safety of bendectin. Teratology. 1978 Feb;17(1):31–35. doi: 10.1002/tera.1420170109. [DOI] [PubMed] [Google Scholar]
  23. Vessey M., Meisler L., Flavel R., Yeates D. Outcome of pregnancy in women using different methods of contraception. Br J Obstet Gynaecol. 1979 Jul;86(7):548–556. doi: 10.1111/j.1471-0528.1979.tb10808.x. [DOI] [PubMed] [Google Scholar]
  24. Windham G. C., Edmonds L. D. Current trends in the incidence of neural tube defects. Pediatrics. 1982 Sep;70(3):333–337. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES